Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database
Sign Up to like & getrecommendations! Published in 2020 at "EClinicalMedicine"
DOI: 10.1016/j.eclinm.2020.100601
Abstract: Background Mogamulizumab (Moga) is a C—C chemokine receptor-4 antibody approved in the United States for relapsed /refractory mycosis fungoides and Sézary syndrome. Few cases reported an increased risk of hepatitis B reactivation and cytomegalovirus (CMV)… read more here.
Keywords: moga; cases reported; hepatitis reactivation; study ... See more keywords
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.
Sign Up to like & getrecommendations! Published in 2017 at "Gastroenterology"
DOI: 10.1053/j.gastro.2017.02.009
Abstract: Hepatitis B reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus (HBV) infection. The population… read more here.
Keywords: hbv; hepatitis reactivation; reactivation; management ... See more keywords
Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Open forum infectious diseases"
DOI: 10.1093/ofid/ofaa080
Abstract: Hepatitis B reactivation (HBR) is a complication of immunosuppression associated with significant morbidity and mortality. To further complicate interpretation of hepatitis B serologies, false positivity can occur in patients with recent intravenous immunoglobulin exposure. This… read more here.
Keywords: hepatitis; recent intravenous; intravenous immunoglobulin; hepatitis reactivation ... See more keywords
Hepatitis B reactivation with pembrolizumab, atezolizumab, and nivolumab: A pharmacovigilance study and literature review.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15127
Abstract: e15127Background: Chronic Hepatitis B virus (HBV) impacts 257 million people worldwide. Chemo- and immunotherapies may predispose to HBV reactivation (HBVr), which can negatively impact oncologic o... read more here.
Keywords: atezolizumab nivolumab; hepatitis; hepatitis reactivation; reactivation ... See more keywords